Mirati has risen to meet one of the most challenging mutations in cancer research by developing KRAZATI, a highly selective and potent oral small-molecule inhibitor of KRAS
Mirati Therapeutics is a commercial stage biotechnology company. (Credit: Mirati Therapeutics, Inc.)
Mirati Therapeutics, a commercial stage biotechnology company, today announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
“KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation. MHRA’s authorization is a significant step towards improving the options available for patients and clinicians in Great Britain,” said Alan Sandler, M.D., chief medical officer, Mirati Therapeutics, Inc. “We are encouraged by the opportunity to bring KRAZATI, a potential best-in-class treatment to qualified patients.”
“Fourteen percent of people living with NSCLC harbour the KRASG12C mutation yet there are limited targeted treatment options for patients with this devastating disease,” said Dr Shobhit Baijal (Consultant Medical Oncologist of The University Hospital Birmingham).
“The expansion of treatment options for NSCLC benefits patients and clinicians alike. As someone intensively involved in the management of lung cancer patients, I look forward to KRAZATI being available for use in clinical practice.”
Source: Company Press Release